This article is an up-to-date overview on research and clinical management issues for drug-drug interactions. As the field has changed dramatically in the last few years, this timely overview is a great opportunity to get updated.
I found this article to be interesting because it provides an assumption-light and efficient procedure to obtain parameter uncertainty in nonlinear mixed-effects models
I like this article because it provides an excellent guidance on how to approach the modeling of QT prolongation in well-designed early phase I studies as a potential alternative approach to a thorough QT study to reliably exclude clinically relevant QTc effects.
qPharmetra provides pharmacometric analysis, clinical pharmacology consulting and custom software tools to help drug companies develop better medicines.
+1 (919) 6519713 (US) / + (31) 618 802292 (Europe)